Publications

CARGO is advancing a pipeline
of transformational next-generation
CAR T-cell therapies for cancer

CARGO will be moving its Corporate Headquarters to 835 Industrial Road, Suite 400, San Carlos, CA 94070 on April 1, 2024

  • CD22 CAR LBCL Supplement, Blood 2021

    Baird et al, Blood 2021

    Open PDF

  • CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 Car T-Cell Trial

    Shah et al, Journal of Clinical Oncology 2021

    Open PDF

  • Outcomes of Patients With Large B-Cell Lymphoma Progressing After Axicabtagene Ciloleucel Therapy

    Spiegel et al, Blood 2021

    Open PDF

  • LBCL Outcome Post CD19 Appendix

    Spiegel et al, Blood 2021

    Open PDF

  • Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR T Immunotherapies

    Parker et al, Cell Press 2020

    Open PDF